Advances in the Diagnosis and Treatment of Non-small Cell Lung Cancer

Dear Colleagues,

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Unfortunately, the majority of patients are diagnosed with advanced disease, leading to an unfavorable prognosis. Recent studies have demonstrated the involvement of essential genes and signaling pathways in the tumorigenesis and progression of NSCLC. A better understanding of this malignancy has led to the discovery of novel molecular therapeutic strategies. Both targeted therapies and immunotherapies have improved prognoses and substantially prolonged the progression-free survival of patients with advanced NSCLC. However, treatment non-responsiveness and rapid disease progression appearing in some patients are challenging.

Currently, targeted treatment therapies for advanced NSCLC patients are based on a wide range of established and emerging molecular biomarkers. The advent and wide-scale implementation of next-generation sequencing (NGS) technologies can contribute to the discovery of a broad range of genetic alterations, particularly those influencing treatment sensitivity and those underlying primary, adaptive, and acquired resistance within cancer cells.

Therefore, we anticipate that this IJMS Special Issue will serve as a compendium of cutting-edge insights, enhancing our understanding of NSCLC. We invite submissions of original research articles as well as reviews in the areas of basic, translational, and clinical NSCLC research. Except for pure clinical studies, we welcome clinical or theoretical model submissions with biomolecular experiments encompassing all aspects of NSCLC. Specifically, we encourage contributions to the following key areas of research:

• Non-small cell lung cancer;
• Precision medicine applications in NSCLC;
• Targeted therapy for NSCLC;
• Immunotherapy in NSCLC;
• Novel therapeutic agents in lung cancer;
• Tumor drug resistance in lung cancer;
• Molecular diagnostic techniques in NSCLC;
• Lung cancer biomarkers—identification and validation;
• Molecular genetics and proteomics in NSCLC;
• Lung cancer pathogenesis;
• Next-generation sequencing (NGS) in lung cancer research.

Dr. Joanna Moes-Sosnowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.